Abstract: Modern medicine has given us effective tools to treat some of the most significant and burdensome diseases. At the same time, it is becoming consistently more challenging and more expensive to develop new therapeutics. A key factor in this trend is that we simply don't understand the underlying biology of disease, and which interventions might meaningfully modulate clinical outcomes and in which patients. To achieve this goal, we are bringing together large amounts of high content data, taken both from humans and from human-derived cellular systems generated in our own lab. Those are then used to learn a meaningful representation of biological states via cutting edge machine learning methods, which enable us to make predictions about novel targets, coherent patient segments, and the clinical effect of molecules. Our ultimate goal is to develop a new approach to drug development that uses high-quality data and ML models to design novel, safe, and effective therapies that help more people, faster, and at a lower cost.
Bio: Daphne Koller is CEO and Founder of insitro, a machine learning-driven drug discovery and development company. Daphne is also co-founder of Engageli, was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years, the co-CEO and President of Coursera, and the Chief Computing Officer of Calico Labs. She is the author of over 300 refereed publications with an h-index of 146. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004, the ACM Prize in Computing in 2008, the ACM AAAI Allen Newell Award in 2019, and the AnitaB.org Technical Leadership Abie Award Winner in 2022. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Association for Artificial Intelligence in 2004, the American Academy of Arts and Sciences in 2014, and the International Society of Computational Biology in 2017.
